CymaBay Therapeutics, Inc. Quarterly Debt-to-equity in % from Q3 2015 to Q4 2023

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
CymaBay Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q3 2015 to Q4 2023.
  • CymaBay Therapeutics, Inc. Debt-to-equity for the quarter ending December 31, 2023 was 63.4 %, a 53.9% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q4 2023 63.4 -74.1 -53.9% Dec 31, 2023
Q3 2023 85.2 -8 -8.58% Sep 30, 2023
Q2 2023 150 +78.6 +110% Jun 30, 2023
Q1 2023 156 +108 +225% Mar 31, 2023
Q4 2022 137 +110 +403% Dec 31, 2022
Q3 2022 93.2 +79 +557% Sep 30, 2022
Q2 2022 71.7 +63.8 +812% Jun 30, 2022
Q1 2022 48 +40.7 +561% Mar 31, 2022
Q4 2021 27.3 +19.9 +268% Dec 31, 2021
Q3 2021 14.2 +6.04 +74% Sep 30, 2021
Q2 2021 7.86 -0.68 -7.97% Jun 30, 2021
Q1 2021 7.26 -1.33 -15.5% Mar 31, 2021
Q4 2020 7.42 -0.7 -8.62% Dec 31, 2020
Q3 2020 8.16 +0.24 +3.03% Sep 30, 2020
Q2 2020 8.54 +0.81 +10.5% Jun 30, 2020
Q1 2020 8.58 +0.32 +3.87% Mar 31, 2020
Q4 2019 8.12 -1.09 -11.8% Dec 31, 2019
Q3 2019 7.92 -2.87 -26.6% Sep 30, 2019
Q2 2019 7.72 -5.34 -40.9% Jun 30, 2019
Q1 2019 8.26 -10.9 -56.8% Mar 31, 2019
Q4 2018 9.21 -29 -75.9% Dec 31, 2018
Q3 2018 10.8 -54 -83.3% Sep 30, 2018
Q2 2018 13.1 -233 -94.7% Jun 30, 2018
Q1 2018 19.1 -139 -87.9% Mar 31, 2018
Q4 2017 38.2 -78.4 -67.2% Dec 31, 2017
Q3 2017 64.8 -13.9 -17.7% Sep 30, 2017
Q2 2017 246 +185 +303% Jun 30, 2017
Q1 2017 158 +102 +184% Mar 31, 2017
Q4 2016 117 +57.4 +96.9% Dec 31, 2016
Q3 2016 78.7 -1.04 -1.3% Sep 30, 2016
Q2 2016 61 Jun 30, 2016
Q1 2016 55.6 Mar 31, 2016
Q4 2015 59.2 Dec 31, 2015
Q3 2015 79.8 Sep 30, 2015
* An asterisk sign (*) next to the value indicates that the value is likely invalid.